Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.34 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 5/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 5/20 | 0.33 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.32 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14316244 | 1.00 | RET (0.34) | RETGPR119SUV39H2EIF2AK4KCNK3 | |
| SCHEMBL12461414 | 1.00 | RET (0.34) | RETGPR119SUV39H2EIF2AK4KCNK3 | |
| SCHEMBL14298329 | 1.00 | RET (0.34) | RETGPR119SUV39H2EIF2AK4KCNK3 | |
| SCHEMBL2147933 | 1.00 | RET (0.34) | RETGPR119SUV39H2EIF2AK4KCNK3 | |
| SCHEMBL17399229 | 1.00 | RET (0.34) | RETGPR119SUV39H2EIF2AK4KCNK3 | |
| SCHEMBL2147571 | 1.00 | RET (0.34) | RETGPR119SUV39H2EIF2AK4KCNK3 | |
| SCHEMBL28913 | 0.93 | EIF2AK4 (0.33) | RETGPR119SUV39H2EIF2AK4KCNK3 | |
| SCHEMBL2147546 | 0.92 | EIF2AK4 (0.33) | RETGPR119SUV39H2EIF2AK4KCNK3 | |
| SCHEMBL2147553 | 0.92 | EIF2AK4 (0.33) | RETGPR119SUV39H2EIF2AK4KCNK3 | |
| SCHEMBL14298636 | 0.92 | EIF2AK4 (0.32) | RETGPR119SUV39H2EIF2AK4KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2608668-B1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | MERCK SHARP & DOHME (US) | 2016-06-01 | — | — | EP | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227971-B2 | Pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-8703784-B2 | Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703784-B2 | Substituted pyrazolo[1,5-a]pyrido[3.2-e]pyrimidin-6-one inhibitors of mammalian target of rapamycin | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| EP-2608668-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | Merck Sharp & Dohme Corp. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20130150353-A1 | Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin | MERCK SHARP & DOHME LLC | 2013-06-13 | — | — | US | disclosed |
| US-20130150353-A1 | Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin | MERCK SHARP & DOHME LLC | 2013-06-13 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-12-20 | — | — | US | disclosed |
| WO-2012027234-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | SCHERING CORPORATION (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2011090935-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011090935-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150353-A1 | Fused Tricyclic Inhibitors of Mammalian Target of Rapamycin | MTOR, RICTOR, RPTOR | RET 506/4885GPR119 3605/4885SUV39H2 2712/4885 |
| US-20120322791-A1 | PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS | MTOR, RICTOR, RPS6KA5 | RET 148/4885GPR119 1809/4885SUV39H2 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.